

<b>Classification</b>	<b>n (%)</b>	<b>PFS</b>		<b>OS</b>	
		<b>% Patients (4-year survival)</b>	<b>P log-rank</b>	<b>% Patients (4-year survival)</b>	<b>P log-rank</b>
<b>All</b>	121 (100)				
<b>Status at allo-HSCT</b>			0.297		<b>0.023</b>
CR	73 (60)	45		55	
PR	29 (24)	27		29	
SD/PD	19 (16)	21		27	
<b>Conditioning</b>			0.050		<b>0.011</b>
MAC	17 (14)	0		10	
RIC	104 (86)	44		51	
<b>Donor type</b>			0.182		0.500
MSD	54 (44.6)	41		49	
MUD	35 (28.9)	29		44	
Haploidentical	23 (19)	52		56	
CB	9 (7.4)	38		41	
<b>Period of transplant</b>			0.30		0.23
Before 2010	29 (24)	30		40	
2010 to 2015	39 (32)	35		42	
After 2015	53 (44)	49		57	

Allo-HSCT: allogeneic-haematopoietic stem cell transplantation; CB: cord blood; CR: complete remission; MAC: myeloablative conditioning; MSD: matched sibling donor; MUD: matched unrelated donor; OS: overall survival; PFS: progress-free survival; PR: partial remission; RIC: reduced intensity conditioning; SD/PD: stable diseases/progressive-free disease  
Values in bold are statistically significant.